238 related articles for article (PubMed ID: 16270629)
1. VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation.
Geisen C; Watzka M; Sittinger K; Steffens M; Daugela L; Seifried E; Müller CR; Wienker TF; Oldenburg J
Thromb Haemost; 2005 Oct; 94(4):773-9. PubMed ID: 16270629
[TBL] [Abstract][Full Text] [Related]
2. VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans.
Limdi NA; Beasley TM; Crowley MR; Goldstein JA; Rieder MJ; Flockhart DA; Arnett DK; Acton RT; Liu N
Pharmacogenomics; 2008 Oct; 9(10):1445-58. PubMed ID: 18855533
[TBL] [Abstract][Full Text] [Related]
3. VKORC1 V66M mutation in African Brazilian patients resistant to oral anticoagulant therapy.
Orsi FA; Annichino Bizzacchi JM; de Paula EV; Ozelo MC; Langley MR; Weck KE
Thromb Res; 2010 Sep; 126(3):e206-10. PubMed ID: 20615525
[TBL] [Abstract][Full Text] [Related]
4. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups.
Limdi NA; Wadelius M; Cavallari L; Eriksson N; Crawford DC; Lee MT; Chen CH; Motsinger-Reif A; Sagreiya H; Liu N; Wu AH; Gage BF; Jorgensen A; Pirmohamed M; Shin JG; Suarez-Kurtz G; Kimmel SE; Johnson JA; Klein TE; Wagner MJ;
Blood; 2010 May; 115(18):3827-34. PubMed ID: 20203262
[TBL] [Abstract][Full Text] [Related]
5. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.
Yuan HY; Chen JJ; Lee MT; Wung JC; Chen YF; Charng MJ; Lu MJ; Hung CR; Wei CY; Chen CH; Wu JY; Chen YT
Hum Mol Genet; 2005 Jul; 14(13):1745-51. PubMed ID: 15888487
[TBL] [Abstract][Full Text] [Related]
6. New genetic variant that might improve warfarin dose prediction in African Americans.
Schelleman H; Brensinger CM; Chen J; Finkelman BS; Rieder MJ; Kimmel SE
Br J Clin Pharmacol; 2010 Sep; 70(3):393-9. PubMed ID: 20716240
[TBL] [Abstract][Full Text] [Related]
7. Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy.
Limdi NA; Wiener H; Goldstein JA; Acton RT; Beasley TM
Blood Cells Mol Dis; 2009; 43(1):119-28. PubMed ID: 19297219
[TBL] [Abstract][Full Text] [Related]
8. Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin.
Yuen E; Gueorguieva I; Wise S; Soon D; Aarons L
J Pharmacokinet Pharmacodyn; 2010 Feb; 37(1):3-24. PubMed ID: 19941044
[TBL] [Abstract][Full Text] [Related]
9. VKORC1 polymorphisms in Brazilians: comparison with the Portuguese and Portuguese-speaking Africans and pharmacogenetic implications.
Suarez-Kurtz G; Amorim A; Damasceno A; Hutz MH; de Moraes MO; Ojopi EB; Pena SD; Perini JA; Prata MJ; Ribeiro-dos-Santos A; Romano-Silva MA; Teixeira D; Struchiner CJ
Pharmacogenomics; 2010 Sep; 11(9):1257-67. PubMed ID: 20860466
[TBL] [Abstract][Full Text] [Related]
10. Thirteen novel VKORC1 mutations associated with oral anticoagulant resistance: insights into improved patient diagnosis and treatment.
Watzka M; Geisen C; Bevans CG; Sittinger K; Spohn G; Rost S; Seifried E; Müller CR; Oldenburg J
J Thromb Haemost; 2011 Jan; 9(1):109-18. PubMed ID: 20946155
[TBL] [Abstract][Full Text] [Related]
11. VKORC1 haplotypes in five East-Asian populations and Indians.
Lee MT; Chen CH; Chuang HP; Lu LS; Chou CH; Chen YT; Liu CY; Wen MS; Lu JJ; Chang CF; Wu JY; Chen YT
Pharmacogenomics; 2009 Oct; 10(10):1609-16. PubMed ID: 19842934
[TBL] [Abstract][Full Text] [Related]
12. Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans.
Limdi NA; Arnett DK; Goldstein JA; Beasley TM; McGwin G; Adler BK; Acton RT
Pharmacogenomics; 2008 May; 9(5):511-26. PubMed ID: 18466099
[TBL] [Abstract][Full Text] [Related]
13. Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles.
Oldenburg J; Bevans CG; Fregin A; Geisen C; Müller-Reible C; Watzka M
Thromb Haemost; 2007 Sep; 98(3):570-8. PubMed ID: 17849045
[TBL] [Abstract][Full Text] [Related]
14. Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population.
Veenstra DL; You JH; Rieder MJ; Farin FM; Wilkerson HW; Blough DK; Cheng G; Rettie AE
Pharmacogenet Genomics; 2005 Oct; 15(10):687-91. PubMed ID: 16141794
[TBL] [Abstract][Full Text] [Related]
15. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations.
Wu AH; Wang P; Smith A; Haller C; Drake K; Linder M; Valdes R
Pharmacogenomics; 2008 Feb; 9(2):169-78. PubMed ID: 18370846
[TBL] [Abstract][Full Text] [Related]
16. The effect of CYP2C9, VKORC1 genotypes and old age on warfarin pharmacologic sensitivity in korean patients with thromboembolic disease.
Moon HW; Noh J; Yun YM; Kim HY; Yun IJ; Song J; Kim JQ
Ann Clin Lab Sci; 2011; 41(3):229-35. PubMed ID: 22075505
[TBL] [Abstract][Full Text] [Related]
17. CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing.
Scott SA; Jaremko M; Lubitz SA; Kornreich R; Halperin JL; Desnick RJ
Pharmacogenomics; 2009 Aug; 10(8):1243-55. PubMed ID: 19663669
[TBL] [Abstract][Full Text] [Related]
18. Positive selection in the chromosome 16 VKORC1 genomic region has contributed to the variability of anticoagulant response in humans.
Patillon B; Luisi P; Blanché H; Patin E; Cann HM; Génin E; Sabbagh A
PLoS One; 2012; 7(12):e53049. PubMed ID: 23285254
[TBL] [Abstract][Full Text] [Related]
19. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups.
Scott SA; Khasawneh R; Peter I; Kornreich R; Desnick RJ
Pharmacogenomics; 2010 Jun; 11(6):781-91. PubMed ID: 20504253
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of combined CYP2C9 and VKORC1 genotypes in Japanese patients requiring warfarin.
Miyagata Y; Nakai K; Sugiyama Y
Int Heart J; 2011; 52(1):44-9. PubMed ID: 21321468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
